Provocative tests of prolactin before, during and after long-term danazol treatment in patients with endometriosis

Dimitrios Panidis, D Panidis, D Vavilis, Dimitrios Vavilis, D Rousso, E Panidou, Andreas P. Kalogeropoulos, A Kalogeropoulos
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 1992 · vol. 6(1) , pp. 19–24 · doi:10.3109/09513599209081002 · PMID:1580163 · W2055206090
article OA: closed CC0 ⤵ 14 in-corpus citations
View on OpenAlex View on PubMed View at publisher

Abstract

Ten patients suffering from endometriosis were treated with danazol at a dose of 200 mg three times daily for 6 months. To evaluate prolactin secretion, a thyrotropin releasing hormone (TRH) test and an insulin challenge test were carried out in the follicular phase before treatment, during the 6th month of treatment and after the reappearance of the second menses. The same tests were also performed, only once, in the follicular phase of ten normal women. The absence of a significant difference in basal prolactin levels as well as the response to the TRH and insulin challenge tests between controls and patients with endometriosis, before and after danazol treatment, support the view that hyperprolactinemia should not be considered as a cause of infertility in endometriotic women. Furthermore, the significant reduction of prolactin response to provocative tests during danazol treatment may be associated with the low estrogen levels caused by the medication. Finally, the inadequate prolactin response to insulin-induced hypoglycemia in patients with endometriosis and in normal women shows that this provocative test is not so effective for hypothalamic stimulation of prolactin.

My notes (saved in your browser only)

Condition tags

endometriosisinfertility

MeSH descriptors

Danazol Endometriosis Prolactin Adult Danazol Danazol Endometriosis Endometriosis Female Humans Insulin Prolactin Prolactin Thyrotropin-Releasing Hormone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (20)

Cited by (14)

Source provenance

europepmc
last seen: 2026-06-13T06:22:48.782012+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:11:49.821429+00:00
License: CC0 · commercial use OK